Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 1999

View Archived Issues

Progress continues during third quarter in Cantab's clinical development pipeline

Company Profile: Maxia Pharmaceuticals

GelTex successfully completes acquisition of SunPharm

Merger of RiboGene and Cypros begets new company known as Questcor

Results of Aptosyn trial show inhibition of rise in PSA levels in prostate cancer patients

New Cortech compounds selectively and irreversibly inhibit cysteine proteases

Neuroprotective agents in the Boehringer Ingelheim pipeline

Enkephalin-degrading enzyme inhibitors with analgesic and other morphine-like effects

Neuraminidase inhibitors a focus of investigation at Abbott

Modified tetracycline from CollaGenex exerts potent antiarthritic effects in murine model

Takeda presents new series for androgen- or estrogen-dependent disorders

Erythropoietin receptor-modulating agents discovered at Ortho-McNeil

AAPS news: Pfizer finds CP-467688 superior to CP-319340 in terms of pharmacokinetics

News from ACR/ARHP: preliminary safety and efficacy data reported for AnergiX-RA

Efficacy and safety of darbufelone described at recent congress

New anti-HCMV compound from BioChem Pharma shows favorable PK profile in mice

Tumor regressions, good safety reported for CCI-779 at international conference

AxyS discontinues further development of APC-2059 in psoriasis

Pfizer discusses preclinical PK of new MTP inhibitor, CP-346086, at 1999 AAPS meeting

AnorMED's platinum-based cancer treatment enters phase I clinical trials

AACR-NCI-EORTC meeting highlights: phase I data reported for Lilly cryptophycin analogue

AZT prodrug associated with increased exposure to AZT in pregnancy

ImmunoGen reports positive preclinical data for TAP, intention to speed up development

Oral bioavailability of AM-188 markedly improved by prodrugs: preclinical studies

News from AASP: preclinical PK data for PNU-179954 support further development

XTL and Roche to evaluate HCV therapeutics

SSP and Nippon Kayaku codevelop antifungal triazole

Human pharmacokinetics of OPC-41061 reported at 1999 AAPS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...